The NASH Pipeline: Replete With Targets And New Compounds
The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.
You may also be interested in...
Gilead presented early data for combinations of its three mechanisms in NASH, but analysts noted the findings may undercut its lead candidate selonsertib. Plus EASL takeaways for Genfit, NGM and Madrigal.
Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space as the European Association for the Study of the Liver annual meeting approaches.
With a Phase II AOC3 inhibitor and a pair of preclinical partnerships with RNAi companies, the German pharma is taking its time to investigate a variety of approaches to the multi-factorial disease.